TY  - JOUR
AU  - Mielke, Orell
AU  - Bril, Vera
AU  - Cornblath, David R
AU  - Lawo, John-Philip
AU  - van Geloven, Nan
AU  - Hartung, Hans-Peter
AU  - Lewis, Richard A
AU  - Merkies, Ingemar S J
AU  - Sobue, Gen
AU  - Durn, Billie
AU  - Shebl, Amgad
AU  - van Schaik, Ivo N
AU  - PATH study group
PY  - 2019
DO  - 10.1111/jns.12303
UR  - http://hdl.handle.net/10668/13448
T2  - Journal of the peripheral nervous system : JPNS
AB  - In patients with chronic inflammatory demyelinating polyneuropathy (CIDP), intravenous immunoglobulin (IVIG) is recommended to be periodically reduced to assess the need for ongoing therapy. However, little is known about the effectiveness of...
LA  - en
KW  - Privigen
KW  - chronic inflammatory demyelinating polyneuropathy (CIDP)
KW  - inflammatory neuropathy cause and treatment (INCAT)
KW  - intravenous immunoglobulin (IVIG)
KW  - polyneuropathy and treatment with Hizentra (PATH)
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunoglobulin G
KW  - Immunoglobulins, Intravenous
KW  - Immunologic Factors
KW  - Male
KW  - Middle Aged
KW  - Outcome Assessment, Health Care
KW  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
KW  - Young Adult
TI  - Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
TY  - research article
VL  - 24
ER  -